US 12,441,685 B2
Compounds and methods for treating cancer
James Bradner, Weston, MA (US); Michael Erb, Boston, MA (US); and Jun Qi, Sharon, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Nov. 7, 2023, as Appl. No. 18/503,556.
Application 18/503,556 is a division of application No. 17/158,759, filed on Jan. 26, 2021, granted, now 11,845,728.
Application 17/158,759 is a division of application No. 16/575,733, filed on Sep. 19, 2019, granted, now 10,934,256, issued on Mar. 2, 2021.
Application 16/575,733 is a division of application No. 15/577,845, granted, now 10,464,897, issued on Nov. 5, 2019, previously published as PCT/US2016/035641, filed on Jun. 3, 2016.
Claims priority of provisional application 62/171,783, filed on Jun. 5, 2015.
Prior Publication US 2024/0092735 A1, Mar. 21, 2024
Int. Cl. C07D 211/44 (2006.01); A61P 35/00 (2006.01); C07D 211/58 (2006.01); C07D 213/30 (2006.01); C07D 239/78 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 413/04 (2006.01); C07D 471/04 (2006.01)
CPC C07D 211/44 (2013.01) [A61P 35/00 (2018.01); C07D 211/58 (2013.01); C07D 213/30 (2013.01); C07D 239/78 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 413/04 (2013.01); C07D 471/04 (2013.01)] 20 Claims
 
1. A compound of formula IV:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Z1-Z2 is C(O)—O, O—C(O), C(O)—S, S—C(O), C(O)—NR—NR, or NR—NR—C(O);
each R is independently H or C1-C3 alkyl;
n4 and p4 are each independently 0, 1, 2, 3, 4, or 5;
m4 and o4 are each independently 0, 1, 2, 3, or 4;
each R41, each R42, and each R43 are independently halogen, OH, unsubstituted or substituted C1-C6 alkyl, or unsubstituted or substituted C1-C6 alkoxy;
each R44 is independently halogen, OH, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C1-C6 alkoxy, (CH2)q4—NH2, (CH2)q4—NH—C1-C6 alkyl, or (CH2)q4—N(C1-C6 alkyl)2; and
q4 is 0, 1, 2, 3, 4, 5, or 6.